Intelligent Bio Solutions Expands Forensic Drug Testing in Texas Through Strategic Partnership
TL;DR
Intelligent Bio Solutions Inc. (NASDAQ: INBS) gains a competitive edge in the U.S. Forensic Use Only Market through its alliance with SMARTOX, showcasing the demand for its innovative drug screening technology.
INBS's fingerprint sweat-based drug screening system offers a rapid, non-invasive alternative to traditional tests, with over 7,000 tests conducted, highlighting its efficiency and ease of use.
The deployment of INBS's Intelligent Fingerprinting Drug Screening Readers improves dignity and efficiency in drug testing, contributing to safer and more humane corrections and rehabilitation environments.
Discover how INBS's cutting-edge fingerprint sweat analysis technology is transforming drug testing with over 1,500 tests in 2024 alone, offering a glimpse into the future of non-invasive diagnostics.
Found this article helpful?
Share it with your network and spread the knowledge!
The collaboration between Intelligent Bio Solutions Inc. (NASDAQ: INBS) and SMARTOX, a Texas leader in drug and alcohol screening services, has catalyzed a notable expansion in the forensic drug testing market. With the deployment of more than 50 INBS Intelligent Fingerprinting Drug Screening Readers and the completion of over 7,000 tests, including 1,500 in 2024, this partnership underscores the escalating demand for innovative drug testing solutions. The INBS technology, which utilizes fingerprint sweat analysis, presents a rapid, non-invasive alternative to conventional urine and saliva tests, enhancing both efficiency and user dignity in testing scenarios such as corrections, rehabilitation, and drug courts.
This technological advancement is not only revolutionizing the way drug tests are conducted but also setting the stage for broader applications. INBS is actively pursuing FDA clearance for its codeine opiate test, with plans to venture into workplace drug testing later this year. The Intelligent Fingerprinting Drug Screening System, designed for portability, hygiene, and cost-effectiveness, screens for recent use of commonly abused substances, including opiates, cocaine, methamphetamine, and cannabis. Its ability to deliver results in under ten minutes represents a significant boon for employers in safety-critical industries, offering a swift and dignified testing method.
The partnership with SMARTOX not only validates the efficacy and reliability of INBS's technology but also signifies a critical milestone in the company's expansion within the U.S. forensic market. As INBS continues to innovate and navigate the regulatory landscape, its solutions are anticipated to address the pressing challenges of drug testing across various sectors. By providing a faster, more efficient, and less invasive alternative to traditional methods, INBS is poised to make a lasting impact on the industry, enhancing safety and compliance in workplaces and beyond.
Curated from InvestorBrandNetwork (IBN)
